key: cord-0021826-x3uxbeko authors: Rafii, Hanadi; Ionescu, Irina; Ruggeri, Annalisa; Garnier, Federico; Ballot, Caroline; Bensoussan, Danièle; Chabannon, Christian; Dazey, Bernard; De Vos, John; Gautier, Eric; Giraud, Christine; Larghero, Jérome; Cras, Audrey; Mialou, Valérie; Persoons, Virginie; Pouthier, Fabienne; Thibert, Jean-Baptiste; Dalle, Jean-Hugues; Michel, Gerard; Sinayoko, Mahamadou; Kenzey, Chantal; Volt, Fernanda; Rocha, Vanderson; Bay, Jacques-Olivier; Rubio, Marie-Thérèse; Robin, Marie; Faucher, Catherine; Marry, Evelyne; Gluckman, Eliane title: Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC) date: 2021-10-07 journal: Bone Marrow Transplant DOI: 10.1038/s41409-021-01477-6 sha: 8c4d96b0abcc9a183311cd8e70594e4987c2c8da doc_id: 21826 cord_uid: x3uxbeko nan international registries published recommendations to maintain safe access to urgent hematopoietic stem cell transplants [9] [10] [11] . They recommended to cryopreserve all grafts and give preference to domestic donors and cord blood over international ones. This study aims to retrospectively review the impact of the Covid-19 pandemic on the collection and utilization of unrelated umbilical cord blood units (UCB) facilitated by the French Cord Blood Banks (CBB) Network during 2020 in comparison to 2019. From January to December 2020, 4392 UCB were collected by the French CBB Network, compared to 7989 units in 2019; there was a 45% decrease in the collection activity in 2020. The impact was most prominent during the 2-month lockdown period in France (March 17th through May 10th, 2020) when UCB harvesting activity was totally stopped (Fig. 1a) . A total of 154 UCB units were facilitated by the French CBB Network in 2020 to transplant both national (96 units) and international recipients (58 units). No significant difference in indications for UCB transplantation (UCBT) was observed between national and international patients. Median age at UCBT was 31.8 years (0.2-70) and was lower for national recipients (median of 14.3 years) compared to international ones (median of 44.8 years). Fifty-five national recipients and 49 international recipients of UCBT were children (<18 years). Fifty-eight units provided by international CBB were imported to transplant national recipients and 58 units provided by French CBB Network were exported for international patients. Most countries involved in UCB exchange activity with the French CBB Network in 2020 were in Europe (44%) and USA (36%). There was 24% decrease in unit exchange with the American CBB (42 units in 2020 vs. 55 in 2019) but we did not observe an impact on the global exchange activity in Europe (51 units both in 2020 and 2019). Release activity from the French CBB Network inventory involved a total 96 units in 2020 (vs 105 in 2019). Fifty-eight units (60%) were released to transplant international recipients with a 21% reduction compared to the previous year (58 in 2020 vs 73 units in 2019) due to international borders closures that severely impacted the export of stem cell products to recipients outside of France (Fig. 1b) . Thirty-eight units (40%) were used to transplant national recipients (Fig. 1c) There was no statistically significant difference in cell doses of the UCB used for transplantation (collected TNC x10 7 /kg of 4.3 in 2020 vs 5.9 in 2019, p = 0.44). Of the 1429 requests issued in 2020 for harvesting unrelated donor (bone marrow or peripheral blood stem cell) grafts, 392 were canceled resulting in a cancellation rate of 26% of the harvesting requests issued in 2020 compared to 28% (405/1454) of those issued in 2019. The donor-related causes represented 46% of the reasons for cancellation in 2020 and 54% of those in 2019. However, we do not have the information if the cancellation was directly related to COVID 19. Finally, of the 170 adult donor transplants unexpectedly canceled for donor-related causes in 2020, 13 (8%) transplants were performed using UCB as stem cell source (in comparison to 9 UCBT (4%) of the 222 adult donor transplants unexpectedly canceled in 2019). The use of UCB for transplantation decreased worldwide in recent years with the development of haploidentical transplants. However, UCB remains a valuable stem cell source especially for ethnic minorities. UCB is a major resource during emergency situations (nuclear accidents, epidemics..) impacting the collection of blood and marrow as the units are typed, cryopreseved and ready for immediate use. UCB proved to be of critical importance during the current Covid-19 pandemic, mainly in its early phase due to strict lockdown in many countries, international border closures and uncertainty related to COVID-19-delays in adult donor cell procurement. Having UCB readily available in the CBB allowed to bypass the complexity of stem cell procurement process and helped to transplant urgent patients rapidly and with safe products that had not been exposed to SARS-CoV-2. Also important, the use of UCB is an attractive solution for skipping the adult donor work-up and collection which implicates hospital visits, consequently, increasing the potential for donor exposure to viral contamination. Moreover, hospital access is usually very restricted in times of sanitary crisis like the one we are currently experiencing with SARS-CoV-2. UCB allowed to maintain the transplant activity in France and avoid delaying urgent transplants during the pandemic. The impact was more prominent at the domestic level probably due to easier logistic for their national use. Simpler processes associated with unit procurement together with rapid unit availability and product safety may explain why the release of UCB was not slowed by the pandemic, with roughly similar number of units released by the French CBB Network in 2020 and 2019. The SARS-CoV-2 pandemic highlighted the added value of this Worldwide network for blood & marrow transplantation. Changes in hematopoietic cell transplantation practices in response to COVID-19: a survey from the worldwide network for blood & marrow transplantation The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage Impact of COVID-19 and future emerging viruses on hematopoietic cell transplantation and other cellular therapies COVID-19 pandemic and impact on hematopoietic stem cell transplantation Addressing the impact of the coronavirus disease 2019 (COVID-19) pandemic on hematopoietic cell transplantation: learning networks as a means for sharing best practices World Marrow Donor Association. (WMDA) information on COVID-19. https:// share.wmda.info/pages/viewpage.action?pageId=344866320 European Society for Blood and Marrow Transplantation et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy EBMT recommendation update WBMT and the CIBMTR Health Services and International Studies Committee et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the worldwide network for blood and marrow transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee Interim guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy patients COVID-19 rapid guideline: haematopoietic stem cell transplantation. London: National Institute for Health and Care Excellence (UK); 2021 This work was supported by a Monaco Government grant to Eurocord / Monacord at the Centre Scientifique de Monaco and by a grant of the "Cordons de Vie" Association, Monaco. All authors contributed to manuscript preparation: conception and design of the study (EM, EG The authors declare no competing interests. Correspondence and requests for materials should be addressed to Hanadi Rafii.Reprints and permission information is available at http://www.nature.com/ reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.